ArticleToxicology reports2024
An oral developmental toxicity study of generic pesticide pinoxaden in rabbits.
Article in Toxicology reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The safety assessment of pinoxaden by the Joint Meeting on Pesticide Residues (JMPR) established a NOAEL of 30 mg/kg bw/day for maternal and embryo/fetal toxicity from a rabbit developmental toxicity study. However, the Pesticide Peer Review Expert meeting (EFSA) lowered the NOAEL to 10 mg/kg bw/day due to observed diaphragm malformations in one developmental toxicity study in rabbits, proposing a classification for developmental effects as Category 2 R63 or H361d. Both JMPR and EFSA set the Acceptable Daily Intake (ADI) at 0.1 mg/kg bw/day, derived from a 2-year rat study NOAEL with a safety factor of 100, but EFSA also supported ADI by teratology study in rabbits. The current prenatal developmental toxicity study on pinoxaden aimed to elucidate and clarify the potential teratogenic effects and could provide supplementary data for determining the ADI for pinoxaden. The study design exceeded the OECD TG 414 by including an assessment of internal organs. The test item was orally administered by gavage daily from day 6 to day 28 of gestation to three groups of animals, each composed of 21 females, in dose levels of 0, 10 and 30 mg/kg/bw/day. One female from the 30 mg/kg/bw/day dose group was euthanized in extremis on Day 27
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.